Hanwha and SoftBank could exit the advanced biomaterials developer in the offering, which will follow more than $870m in funding.
US-based advanced materials producer Zymergen has filed for a $100m initial public offering that would provide exits for conglomerate Hanwha and internet and telecommunications group SoftBank.
Zymergen is developing technology that can precision-engineer microorganisms to produce biomolecules used in the manufacturing processes of a variety of products across the electronics, personal care and agricultural sectors.
The company expects to deploy the IPO proceeds in commercialisation activities, the launch of new products and the development of its biofacturing platform. It…
